> ## Content Index
> Fetch the complete content index at: https://venture-block.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# BiomX Advances with Phase 2b Trial Initiation, Wall Street Analyst Reaffirms $15 Price Target
- URL: https://venture-block.com/biomx-advances-with-phase-2b-trial-initiation-wall-street-analyst-reaffirms-15-price-target/
- Published: 2025-07-18T17:07:31.000Z
- Updated: 2026-10-25T22:01:58.000Z
- Author: Venture Block
- Tags: Wall Street Wire

## **H.C. Wainwright maintains bullish outlook as phage therapy company advances toward pivotal 2026 data readout**

BiomX Inc. (NYSE: PHGE) reached a significant development milestone this week with the successful initiation of patient dosing in its Phase 2b trial for BX004, a breakthrough phage therapy targeting life-threatening lung infections in cystic fibrosis patients. The achievement prompted H.C. Wainwright to reiterate its Buy rating and $15 price target, representing substantial upside potential from current trading levels around $0.4.

The Phase 2b trial marks a pivotal advancement for BiomX’s lead cystic fibrosis program, which has already demonstrated remarkable efficacy in earlier studies. In the company’s Phase 1b/2a trial, 14.3% of patients completely cleared chronic Pseudomonas aeruginosa infections after just 10 days of treatment, an outcome rarely seen in this patient population, including individuals who had carried infections for over a decade.

> “This first patient dosing marks a significant milestone for our BX004 program and for CF patients with chronic P. aeruginosa infections who desperately need new options,” said Jonathan Solomon, BiomX’s Chief Executive Officer.

The randomized, double-blind, placebo-controlled study will evaluate approximately 60 patients over an 8-week treatment period, with topline results expected in the first quarter of 2026.

## Strong Analyst Support Reflects Growing Confidence

H.C. Wainwright’s maintained Buy rating and $15 price target reflects the firm’s confidence in BiomX’s dual-asset approach. The analyst’s valuation model assigns equal weight to the company’s two lead programs: BX004 for cystic fibrosis infections (52% contribution) and BX211 for diabetic foot osteomyelitis (48% contribution).

The research firm’s clinical net present value model assumes BiomX will secure an ex-U.S. partner with a 23% royalty arrangement, while identifying multiple upside catalysts including higher market penetration, additional indications, and expanded international opportunities.

BX004 has already received significant regulatory support, securing both Fast Track designation and Orphan Drug status from the FDA. These designations provide accelerated review processes and seven years of market exclusivity, potentially streamlining the path to approval for this urgently needed treatment.

## Military Validation Adds Strategic Value

BiomX’s investment thesis extends beyond traditional biotech metrics, bolstered by $40 million in non-dilutive funding previously received from the U.S. Defense Health Agency for its BX211 diabetic foot program. This military backing validates the technology while preserving shareholder value—a significant advantage in an industry typically dependent on dilutive equity financing.

The Pentagon’s investment reflects urgent battlefield needs, as CEO Solomon noted that military medical personnel are “seeing soldiers coming out of the Ukraine war with extremely antibiotic-resistant infections.” This dual-use application positions BiomX’s phage therapies to address both civilian healthcare crises and national security concerns.

## Addressing Massive Unmet Medical Needs

BiomX’s programs target conditions with enormous unmet medical needs and limited treatment options. For diabetic foot osteomyelitis, no new drugs have been approved in over 20 years, despite the condition leading to approximately 160,000 amputations annually in the U.S. alone. The company’s successful Phase 2 DANCE trial demonstrated statistically significant improvements in wound healing, with treated patients showing greater than 40% better outcomes compared to placebo by week 10.

In cystic fibrosis, chronic lung infections remain the leading cause of death despite modern treatments. BiomX’s phage cocktail approach offers a fundamentally different mechanism than traditional antibiotics, potentially overcoming resistance issues that limit current therapies.

As the global antibiotic resistance crisis intensifies and governments prioritize antimicrobial innovation, BiomX’s validated phage therapy platform positions the company at the forefront of a potential paradigm shift in infectious disease treatment. With analyst price targets suggesting significant upside potential and multiple upcoming catalysts, BiomX represents a compelling opportunity in the evolving biotech landscape.

####   
**Recent News Highlights from BiomX**

*Disclaimer & Disclosure: This article is a form of paid promotional article. The Author, Wall Street Wire, has received compensation from BiomX Inc for promotional media services provided on an ongoing subscription basis. This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire are available* [*wallstwire.ai/disclosures*](https://wallstwire.ai/disclosures?ref=venture-block.com)*. We are not responsible for any price targets or market research figures that may be cited in this article nor do we endorse them, they are quoted based on publicly available news reports and additional price targets or figures may exist that may not have been quoted. Readers are advised to refer to the full reports mentioned on various systems and the disclaimers/disclosures they may be subject to.*